tetano
Editor, Senior Moderator
Clin Kidney J
. 2023 Jun 24;16(12):2447-2460.
doi: 10.1093/ckj/sfad147. eCollection 2023 Dec. Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patients
Louise Platen[SUP] 1 [/SUP], Bo-Hung Liao[SUP] 2 [/SUP], Myriam Tellenbach[SUP] 1 [/SUP], Cho-Chin Cheng[SUP] 2 [/SUP], Christopher Holzmann-Littig[SUP] 2 3 [/SUP], Catharina Christa[SUP] 2 [/SUP], Christopher Dächert[SUP] 4 [/SUP], Verena Kappler[SUP] 1 [/SUP], Romina Bester[SUP] 2 [/SUP], Maia Lucia Werz[SUP] 1 [/SUP], Emely Schönhals[SUP] 1 [/SUP], Eva Platen[SUP] 5 [/SUP], Peter Eggerer[SUP] 6 [/SUP], Laëtitia Tréguer[SUP] 7 [/SUP], Claudius Küchle[SUP] 1 [/SUP], Christoph Schmaderer[SUP] 1 [/SUP], Uwe Heemann[SUP] 1 7 [/SUP], Oliver T Keppler[SUP] 4 7 [/SUP], Lutz Renders[SUP] 1 8 [/SUP], Matthias Christoph Braunisch[SUP] 1 [/SUP], Ulrike Protzer[SUP] 2 7 9 [/SUP]
Affiliations
Background: Individuals on haemodialysis (HD) are more vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection than the general population due to end-stage kidney disease-induced immunosuppression.
Methods: A total of 26 HD patients experiencing SARS-CoV-2 infection after a third vaccination were matched 1:1 with 26 of 92 SARS-CoV-2-naïve patients by age, sex, dialysis vintage and immunosuppressive drugs receiving a fourth vaccination with a messenger RNA-based vaccine. A competitive surrogate neutralization assay was used to monitor vaccination success. To determine infection neutralization titres, Vero-E6 cells were infected with SARS-CoV-2 variants of concern (VoCs), Omicron sublineage BA.1, BA.5 and BQ.1.1. The 50% inhibitory concentration (IC50, serum dilution factor 1:x) was determined before, 4 weeks after and 6 months after the fourth vaccination.
Results: A total of 52 HD patients received four coronavirus disease 2019 (COVID-19) vaccinations and were followed up for a median of 6.3 months. Patient characteristics did not differ between the matched cohorts. Patients without a SARS-CoV-2 infection had a significant reduction of real virus neutralization capacity for all Omicron sublineages after 6 months (P < .001 each). Those patients with a virus infection did not experience a reduction in real virus neutralization capacity after 6 months. Compared with the other Omicron VoC, the BQ.1.1 sublineage had the lowest virus neutralization capacity.
Conclusions: SARS-CoV-2-naïve HD patients had significantly decreased virus neutralization capacity 6 months after the fourth vaccination, whereas patients with a SARS-CoV-2 infection had no change in neutralization capacity. This was independent of age, sex, dialysis vintage and immunosuppression. Therefore, in infection-naïve HD patients a fifth COVID-19 vaccination might be reasonable 6 months after the fourth vaccination.
Keywords: BA.1; BA.5; BQ.1.1; COVID-19 vaccination; haemodialysis.
. 2023 Jun 24;16(12):2447-2460.
doi: 10.1093/ckj/sfad147. eCollection 2023 Dec. Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patients
Louise Platen[SUP] 1 [/SUP], Bo-Hung Liao[SUP] 2 [/SUP], Myriam Tellenbach[SUP] 1 [/SUP], Cho-Chin Cheng[SUP] 2 [/SUP], Christopher Holzmann-Littig[SUP] 2 3 [/SUP], Catharina Christa[SUP] 2 [/SUP], Christopher Dächert[SUP] 4 [/SUP], Verena Kappler[SUP] 1 [/SUP], Romina Bester[SUP] 2 [/SUP], Maia Lucia Werz[SUP] 1 [/SUP], Emely Schönhals[SUP] 1 [/SUP], Eva Platen[SUP] 5 [/SUP], Peter Eggerer[SUP] 6 [/SUP], Laëtitia Tréguer[SUP] 7 [/SUP], Claudius Küchle[SUP] 1 [/SUP], Christoph Schmaderer[SUP] 1 [/SUP], Uwe Heemann[SUP] 1 7 [/SUP], Oliver T Keppler[SUP] 4 7 [/SUP], Lutz Renders[SUP] 1 8 [/SUP], Matthias Christoph Braunisch[SUP] 1 [/SUP], Ulrike Protzer[SUP] 2 7 9 [/SUP]
Affiliations
- PMID: 38046025
- PMCID: PMC10689143
- DOI: 10.1093/ckj/sfad147
Background: Individuals on haemodialysis (HD) are more vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection than the general population due to end-stage kidney disease-induced immunosuppression.
Methods: A total of 26 HD patients experiencing SARS-CoV-2 infection after a third vaccination were matched 1:1 with 26 of 92 SARS-CoV-2-naïve patients by age, sex, dialysis vintage and immunosuppressive drugs receiving a fourth vaccination with a messenger RNA-based vaccine. A competitive surrogate neutralization assay was used to monitor vaccination success. To determine infection neutralization titres, Vero-E6 cells were infected with SARS-CoV-2 variants of concern (VoCs), Omicron sublineage BA.1, BA.5 and BQ.1.1. The 50% inhibitory concentration (IC50, serum dilution factor 1:x) was determined before, 4 weeks after and 6 months after the fourth vaccination.
Results: A total of 52 HD patients received four coronavirus disease 2019 (COVID-19) vaccinations and were followed up for a median of 6.3 months. Patient characteristics did not differ between the matched cohorts. Patients without a SARS-CoV-2 infection had a significant reduction of real virus neutralization capacity for all Omicron sublineages after 6 months (P < .001 each). Those patients with a virus infection did not experience a reduction in real virus neutralization capacity after 6 months. Compared with the other Omicron VoC, the BQ.1.1 sublineage had the lowest virus neutralization capacity.
Conclusions: SARS-CoV-2-naïve HD patients had significantly decreased virus neutralization capacity 6 months after the fourth vaccination, whereas patients with a SARS-CoV-2 infection had no change in neutralization capacity. This was independent of age, sex, dialysis vintage and immunosuppression. Therefore, in infection-naïve HD patients a fifth COVID-19 vaccination might be reasonable 6 months after the fourth vaccination.
Keywords: BA.1; BA.5; BQ.1.1; COVID-19 vaccination; haemodialysis.